| Revenue growth | FY26: 36% YoY; FY27 Target: ₹650 Cr (approx 30% growth). |
|---|---|
| Margins | Expanding: EBITDA margin up from 22% (FY25) to 24% (FY26). |
| Demand visibility | Strong, backed by 700+ filings and 100+ global clients. |
| Management confidence | High, targeting 3x profit growth vs revenue through high-margin complex molecules. |
Growth
FY26 revenue grew 36% YoY to ₹503 Cr; PAT surged 72% to ₹67.4 Cr. EBITDA margins expanded to 24%.
Outlook
Targeting 30-35% topline growth in FY27 (₹650 Cr). Unit 6 Hormone plant completion by Q3CY26; Biologics commercialization H1FY27.
Risks
Regulatory compliance risks across 70+ countries; high concentration in Unit 1 (60% revenue); execution risk in Unit 6.
Earnings Call filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,671.45
- Market cap
- ₹3,810 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.0×Sector 50.4×
- Promoter holding
- 54.86%-0.01% QoQ
- FII holding
- 3.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Kwality Pharmaceuticals Q1 FY27 Results: Net Profit ₹25.6 Cr, Up 115.1% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹25.6 Cr · +115.1% YoY
Kwality Pharmaceuticals Earnings Call: Key Takeaways
Kwality Pharmaceuticals delivered a landmark FY26 with 36% revenue growth and 69% PAT growth, driven by higher-margin oncology products and improved operational efficiencies.
Kwality Pharmaceuticals Q4 FY26 Results: Net Profit ₹25.3 Cr, Up 74.5% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹157.1 Cr (+35.8% YoY) and net profit of ₹25.3 Cr (+74.5% YoY) for Q4 FY26.
- Key figure
- Net profit ₹25.3 Cr · +74.5% YoY